Biktarvy® (bictegravir, emtricitabine & tenofovir alafenamide) is a guidelines-recommended complete single tablet HIV treatment regimen for people living with HIV. This poster reviews the five-year cumulative outcomes of Biktarvy in treatment-naïve PLWH, compared to other current antiretrovirals. Over five years of follow up, Biktarvy was demonstrated to be highly effective in treatment-naïve PLWH across all ages, genders, races, baseline viral load, or CD4 counts, as well as in special populations.